Future Microbiology · 2017 · 67 citations · 26 references
PharmacyInfectious DiseasesPharmacologyAntimicrobial PharmacologyAntimicrobial ResistanceMedical MicrobiologyAntibacterial PharmacologyAntibacterial PharmacotherapyAntibacterial TherapyAntibiotic ResistanceAntimicrobial TherapyCombination Antimicrobial TherapyAntibiotic CombinationsDrug-resistant PathogensFractional Inhibitory Concentration IndexMethicillin-resistant Staphylococcus Aureus Infection TreatmentMethicillin-resistant Staphylococcus Aureus Treatment
Aim: The aim of this study was to evaluate the efficacy of durancin 61A alone or in combination with nisin, pediocin PA-1, reuterin, microcin J25, vancomycin or tetracycline as an inhibitor of resistant clinical pathogens and to shed light on its mode of action. Results: Durancin and reuterin were effective inhibitors of Clostridium difficile, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus. The combination of durancin and reuterin was highly synergistic against C. difficile (fractional inhibitory concentration index = 0.2). Durancin/vancomycin combination was synergistic against S. aureus ATCC® 700699 (fractional inhibitory concentration index = 0.3). Conclusion & future perspective: Durancin 61A alone or combined with other bacteriocins or antibiotics may therefore provide a possible therapeutic option for the treatment of infections by these pathogens.
26